In Section C, individuals will get ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Individuals will get treatment right up until illness progression or perhaps the members are not able to tolerate the study drugs. Doable new methods for that analysis and treatment of AML. https://clinicaltrialrecruitmentf80246.worldblogged.com/37890581/considerations-to-know-about-abbv-744-brd4-inhibitor-cancer-therapy-efficacy